ORIGINAL RESEARCH

# Diagnostic exome sequencing in non-acquired focal epilepsies highlights a major role of GATOR1 complex genes

Martin Krenn , <sup>1</sup> Matias Wagner, <sup>2,3</sup> Christoph Hotzy, <sup>1</sup> Elisabeth Graf, <sup>4</sup> Sandrina Weber, <sup>4</sup> Theresa Brunet, <sup>2</sup> Bettina Lorenz-Depiereux, <sup>4</sup> Gregor Kasprian, <sup>5</sup> Susanne Aull-Watschinger, <sup>1</sup> Ekaterina Pataraia, <sup>1</sup> Elisabeth Stogmann, <sup>1</sup> Alexander Zimprich, <sup>1</sup> Tim M Strom, <sup>2,4</sup> Thomas Meitinger, <sup>2,4</sup> Fritz Zimprich

► Additional material is published online only. To view, please visit the journal online (http://dx.doi.org/10.1136/ jmedgenet-2019-106658).

<sup>1</sup>Department of Neurology, Medical University of Vienna, Vienna Austria <sup>2</sup>Institute of Human Genetics, Technical University Munich. Munich, Bayern, Germany <sup>3</sup>Institute of Neurogenomics, Helmholtz Center Munich, Neuherberg, Bayern, Germany <sup>4</sup>Institute of Human Genetics. Helmholtz Center Munich, Neuherberg, Bayern, Germany <sup>5</sup>Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria

# Correspondence to

Fritz Zimprich, Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria; friedrich.zimprich@meduniwien. ac.at

Received 28 October 2019 Revised 17 January 2020 Accepted 22 January 2020 Published Online First 21 February 2020

#### **ABSTRACT**

**Background** The genetic architecture of non-acquired focal epilepsies (NAFEs) becomes increasingly unravelled using genome-wide sequencing datasets. However, it remains to be determined how this emerging knowledge can be translated into a diagnostic setting. To bridge this gap, we assessed the diagnostic outcomes of exome sequencing (ES) in NAFE.

**Methods** 112 deeply phenotyped patients with NAFE were included in the study. Diagnostic ES was performed, followed by a screen to detect variants of uncertain significance (VUSs) in 15 well-established focal epilepsy genes. Explorative gene prioritisation was used to identify possible novel candidate aetiologies with so far limited evidence for NAFE.

**Results** ES identified pathogenic or likely pathogenic (ie, diagnostic) variants in 13/112 patients (12%) in the genes *DEPDC5*, *NPRL3*, *GABRG2*, *SCN1A*, *PCDH19* and *STX1B*. Two pathogenic variants were microdeletions involving *NPRL3* and *PCDH19*. Nine of the 13 diagnostic variants (69%) were found in genes of the GATOR1 complex, a potentially druggable target involved in the mammalian target of rapamycin (mTOR) signalling pathway. In addition, 17 VUSs in focal epilepsy genes and 6 rare variants in candidate genes (*MTOR*, *KCNA2*, *RBFOX1* and *SCN3A*) were detected. Five patients with reported variants had double hits in different genes, suggesting a possible (oligogenic) role of multiple rare variants.

**Conclusion** This study underscores the molecular heterogeneity of NAFE with GATOR1 complex genes representing the by far most relevant genetic aetiology known to date. Although the diagnostic yield is lower compared with severe early-onset epilepsies, the high rate of VUSs and candidate variants suggests a further increase in future years.



© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Krenn M, Wagner M, Hotzy C, *et al. J Med Genet* 2020;**57**:624–633.

#### INTRODUCTION

Focal epilepsies, in which seizures originate from a circumscribed brain region within one hemisphere, account for 60% of all epilepsy cases. While some of these can be attributed to acquired brain lesions, in one-third, no structural epileptogenic abnormality can be identified. These epilepsies are then referred to as non-lesional or non-acquired focal epilepsies (NAFEs). Although the exact aetiology

often remains unknown, there is emerging evidence for a considerable genetic contribution to NAFE.<sup>3</sup>

This is underlined by gene discoveries in families with monogenic forms of this entity, as exemplified by the first identified epilepsy gene, *CHRNA4*, encoding the α4 subunit of the nicotinic acetylcholine receptor,<sup>4</sup> or more recently by the discovery of *DEPDC5*, *NPRL2* and *NPRL3*, which together form the GATOR1 complex, a negative regulator of the mammalian target of rapamycin (mTOR) pathway.<sup>56</sup>

Owing to the increased availability of genetic data and the rapid advancements in high-throughput sequencing technology, our knowledge about the molecular background of epilepsies is constantly expanding. Large-scale next-generation sequencing (NGS) efforts revealed an enrichment of rare coding variants across all types of non-lesional epilepsies (including NAFE) and thus contributed to elucidate their complex genetic architecture.<sup>7–9</sup>

However, the interpretation of genetic variants in these gene discovery studies is significantly different from the diagnostic real-life setting, in which rigorous criteria have to be applied to establish a genetic diagnosis. The utility of NGS as a diagnostic tool has predominantly been demonstrated for paediatric and mixed cohorts with illdefined phenotypes. 10-13 In contrast, there is a lack of data evaluating diagnostic ES in clinically well-characterised patients with focal epilepsies. One small-scale diagnostic ES study used a targeted analysis approach in 40 patients with NAFE and a suspected genetic background, resulting in a diagnostic yield of 12.5%.<sup>14</sup> Two further studies used narrower panel approaches limited to known focal epilepsy genes, both resulting in hit rates of only less than 2%. <sup>15</sup> These contrasting findings demonstrate the uncertainty about genetic testing outcomes for this relevant epilepsy subgroup, and there is a strong need to evaluate comprehensive genetic-diagnostic approaches in clinically wellcharacterised cohorts.

In this study, we intended to contribute data to this knowledge gap and performed diagnostic exome sequencing (ES) in 112 deeply phenotyped patients with NAFE adhering to strict clinicalgenetic guidelines. Furthermore, we report the

clinical characteristics of patients with genetic diagnoses. Being aware that our current ability to assign definite molecular diagnoses is insufficient, we explored plausible candidate genetic aetiologies for NAFE that need to be replicated in future studies.

#### **METHODS**

## **Patient selection**

All individuals were seen at the Department of Neurology of the Medical University of Vienna, Austria, prior to enrolment. Included subjects underwent a clinical workup comprising brain MRI and video-electroencephalogram (EEG) monitoring. Inclusion criteria were a clinical diagnosis of focal epilepsy and at least one of the following: (1) positive family history (defined as at least one first-degree or two second-degree relatives with a history of seizures), or (2) seizure onset before the age of 25 years or (3) resistance to antiepileptic drug (AED) treatment as defined by the International League Against Epilepsy (ILAE). Exclusion criteria were (1) structural abnormalities on brain MRI (except for hippocampal sclerosis/atrophy) and (2) moderate-to-severe intellectual disability. At recruitment, all patients were at least 18 years old and gave written informed consent.

## ES and data analysis

Singleton (proband-only) ES was performed at the Institute of Human Genetics (Helmholtz Centre/Technical University Munich, Germany). Exomes were enriched in solution with SureSelect Human All Exon Kits 50 Mb V5 (Agilent, Santa Clara, California, USA). DNA fragments were sequenced as 100 bp paired-end runs on an *Illumina HiSeq2500* system (Illumina, San Diego, California USA). <sup>18</sup> The mean average coverage was 155-fold.

The two following bioinformatic pipelines were used:

- SAMtools: Reads were aligned to the UCSC human reference assembly (hg19) using BWA V.0.5.8. Single-nucleotide variants (SNVs) and small insertions and deletions (indel) were detected with SAMtools V.0.1.7.
- 2. GATK: Reads were aligned to the UCSC human reference assembly (hg19) using BWA V.0.5.8. Duplicates were removed using Picard V.2.5.0. Indel realignment, base quality realignment (GATK V.3.6.0) and variant calling (HaplotypeCaller) were done as recommended by GATK practices.

Variants were filtered based on the minor allele frequency (MAF), which was estimated using our in-house database (>18 000 exome datasets) and confirmed by the Genome Aggregation Database (gnomAD). Variant prioritisation was based on autosomal recessive (MAF<0.1%) and dominant (MAF<0.01%) filters.

#### Copy number variant (CNV) analysis

Exome-based CNV analysis was done using ExomeDepth<sup>19</sup> and Pindel.<sup>20</sup> Pathogenic CNVs were confirmed by SNP Array Affymetrix CytoScan 750K Array (Affymetrix, Santa Clara, USA). Scanning was performed by the Affymetrix GeneChip Scanner 3000 7G and data were analysed using the Affymetrix Chromosome Analysis Suite Software V.3.3, hg19.

# Molecular diagnoses according to clinical—genetic guidelines (diagnostic variants)

The initial diagnostic analysis step was targeted to 15 established focal epilepsy genes: CHRNA2, CHRNA4, CHRNB2, DEPDC5, GRIN2A, KCNQ2, KCNQ3, KCNT1, LGI1, NPRL2, NPRL3, PRRT2, RELN, SCN2A and SCN8A.<sup>21</sup> In a second step, to also account for unexpected genotype–phenotype correlations and

phenocopies, we searched for pathogenic and likely pathogenic variants (herein referred to as diagnostic variants) in a comprehensive set of all 455 genes associated with 'epilepsy' in the Online Mendelian Inheritance in Man database (online supplementary table S1). The standard criteria of the American College of Medical Genetics and Genomics (ACMG) were applied for variant interpretation. Missense variants in GATOR1 complex genes (DEPDC5, NPRL2 and NPRL3) were classified based on MAF (according to gnomAD) and the Mendelian Clinically Applicable Pathogenicity Score (M-CAP) in silico prediction, as recently proposed for this genetic subgroup.

# Variants of uncertain significance (VUSs) in 15 focal epilepsy genes

Apart from diagnostic variants, we also reported variants with a possible but (according to diagnostic standards) unconfirmed pathogenic effect, hence classified as VUSs. This screen was stringently limited to non-synonymous (missense and in-frame indel) variants in the 15 genes with an established association with genetic focal epilepsies.<sup>21</sup> We only selected very rare variants with a MAF<0.01%, and we set a combined annotation-dependent depletion (CADD) score threshold of >20 for missense variants to be reported as VUS in a diagnostic setting.

# Rare variants in NAFE candidate genes

To exploratively prioritise potential candidate genes, we searched for rare (MAF<0.01%) non-synonymous (missense, indel, splice-site, frameshift and nonsense) variants in each exome dataset. Variants were manually screened using in silico prediction tools (CADD, sorting intolerant from tolerant (SIFT) and PolyPhen-2 (pph2)),<sup>25-27</sup> gnomAD gene constraint information (z score, probability of being loss-of-function intolerant score (pLI)). In the second step, we searched for anecdotal evidence in the literature potentially linking genes with detected variants to focal epilepsy. This prioritisation intended to identify promising candidate variants without being comprehensive.

# Statistical analyses

The rate of diagnostic (ie, pathogenic and likely pathogenic) variants in the cohort established the diagnostic yield. We further aimed to explore clinical and demographic characteristics (sex, age at seizure onset, history of febrile seizure (FS) and a positive family history for seizures) associated with a molecular diagnosis. Fisher's exact test was used for categorical data, and Mann-Whitney U-test for continuous data. A p value of <0.05 was considered statistically significant. Correction for multiple testing (eg, Bonferroni) was not applied in this clinically oriented study with a relatively small sample size. SPSS V.25.0 was used for statistical analyses.

# RESULTS

#### **Patient characteristics**

Of the included patients, 57% were women (n=64) and 43% were men (n=48). The median age at seizure onset was 15 years (range 1–67 years). Fifty-one per cent (n=57) were diagnosed with temporal lobe epilepsy (TLE), followed by frontal lobe epilepsy (FLE) with 24% (n=27), unclassified focal epilepsy (UFE) with 21% (n=24), parietal lobe epilepsy and occipital lobe epilepsy (OLE) with two patients each. An MRI of the brain was normal in 90% (n=101) and showed hippocampal sclerosis/atrophy in 10% (n=11). One-third (n=37) had a positive family history with at least one first-degree or two second-degree relatives being affected with seizures. Ten patients (9%)

## **Neurogenetics**

 Table 1
 Demographic and clinical features of included patients and associations with diagnostic outcome

Characteristics	n (%)	Genetically solved/ unsolved cases
Sex		
Male	48 (43)	6/42
Female	64 (57)	7/57
Median age at seizure onset, years (range)	15 (1–67)	9/15 (median)*
Seizure focus		
Temporal	57 (51)	4/53
Frontal	27 (24)	5/22
Parietal	2 (2)	0/2
Occipital	2 (2)	2/0
Unclassified	24 (21)	2/22
MRI		
Normal	101 (90)	12/89
Hippocampal sclerosis/atrophy	11 (10)	1/10
Family history		
Positive (at least one first-degree or two second-degree relatives with seizures)	37 (33)	6/31
Negative	75 (67)	7/68
History of FS		
Yes	10 (9)	1/9
No	102 (91)	12/90
AED response		
Responsive	6 (5)	0/6
Resistant	86 (77)	10/76
Undefined	20 (18)	3/17

<sup>\*</sup>Statistically significant, Mann-Whitney U-test: uncorrected p value=0.01. AED, antiepileptic drug; FS, febrile seizure.

had a history of FS preceding afebrile focal seizures. At last documented follow-up, the majority of individuals (77%) was resistant to AED treatment as classified by ILAE. <sup>17</sup> The main clinical and demographic characteristics of all 112 included patients are displayed in table 1.

#### **Diagnostic outcomes**


When strictly using ACMG standard criteria, a diagnostic yield of 9% was achieved with heterozygous diagnostic variants identified in 10/112 individuals. The diagnostic yield was increased to 12% (13/112 individuals) after additionally applying the criteria for the interpretation of GATOR1 complex variants, as recently proposed by Baldassari *et al.*<sup>24</sup>

Of these 13 diagnostic variants, nine were detected by the initial diagnostic analysis, which was limited to 15 established focal epilepsy genes. Four additional diagnoses (STX1B, SCN1A, PCDH19 and GABRG2) could be made after applying the extended approach analysing all 455 genes (online supplementary table S1).

The detected variants eventually classified as pathogenic or likely pathogenic included five truncating variants (frameshift or nonsense), five missense variants, two pathogenic CNVs (microdeletions) and one splice-site variant (online supplementary figure S1).

Diagnostic variants were found in six different epilepsy-associated genes (figure 1). Variants in two genes of the GATOR1 complex (*DEPDC5* and *NPRL3*), a negative regulator of the mTOR signalling pathway, together accounted for 9 of the 13 solved cases (69%). Four truncating and two missense variants were found in *DEPDC5*, while one truncating, one missense variant and one microdeletion were found in (or involving) *NPRL3*, in line with haploinsufficiency being the known pathomechanism. No genetic diagnosis was related to *NPRL2*.

Patients with an established molecular diagnosis after ES had a younger median age at seizure onset compared with cases



**Figure 1** Genes with detected variants in non-acquired focal epilepsy. Number of patients (y-axis) harboring diagnostic variants (orange), VUSs (blue) and candidate genetic aetiologies (grey) reported in this study; genes with detected variants are listed on the x-axis. VUS, variant of uncertain significance.

without a genetic diagnosis (9 vs 15 years, uncorrected p=0.01). Sex, a positive family history for seizures and a history of FS were not significantly associated with a positive genetic diagnosis (table 1).

#### Epilepsy phenotypes of patients with a genetic diagnosis

The nine patients with diagnostic variants in the GATOR1 complex genes *DEPDC5* and *NPRL3* mirrored the broad clinical spectrum of NAFE with a median age of onset of 10 years. In GATOR1-related NAFE, the epilepsy was classified as TLE (n=3), FLE (n=3), UFE (n=2) and OLE (n=1). The family history was positive in six of nine patients. Given the known association with structural brain abnormalities (mainly focal cortical dysplasia), all MRI scans of patients with reported variants in GATOR1 complex genes were re-evaluated by a neuroradiologist, but no focal abnormalities were revealed in retrospect.

We found a likely pathogenic missense variant in *GABRG2* (previously reported as a pathogenic de novo variant)<sup>28</sup> in a female patient with a history of FS starting during the first month of life. Subsequently, she developed bilateral tonic–clonic seizures and focal seizures with and without impaired awareness. MRI-negative OLE was diagnosed due to the visual seizure semiology and the ictal EEG onset in the occipital region.

One pathogenic CNV was a 3 Mb deletion involving *PCDH19* in a female patient diagnosed with MRI-negative FLE, age of 2 years at seizure onset and a negative family history for epilepsy. In contrast to many previously reported patients with this condition, there was no history of FS or cognitive impairment. The clinical course was characterised by severe AED resistance and a high seizure frequency with focal seizures occurring on a daily basis.

The pathogenic missense variant in *SCN1A* was absent from controls, consistently predicted to be deleterious by multiple in silico tools (pph2, SIFT and CADD) and previously reported to be pathogenic according to ClinVar. The patient harbouring this variant suffered from NAFE with suspected left frontal seizure origin and preceding recurrent (partly complex) FS. Seizures were generally well controlled with valproic acid and levetiracetam, whereas oxcarbazepine and felbamate did not lead to satisfying seizure control.

One male patient with a likely pathogenic splice-site variant in *STX1B* was affected by severe treatment-refractory childhood-onset TLE. Aside from multiple AED trials, the patient also underwent epilepsy surgery (anteromedial temporal lobe resection). Brain histology revealed a mild malformation of cortical development (mMCD), which was not detectable by MRI. Subsequently, the patient also underwent deep brain stimulation but experienced ongoing seizures when last seen.

Demographic and clinical details of patients with diagnostic variants are delineated in table 2.

#### VUSs in 15 focal epilepsy genes

Apart from diagnostic variants according to strict clinical standards, we sought to identify further relevant rare variants, that is to say, VUSs in the 15 well-established focal epilepsy genes. We detected 17 VUSs (16 missense variants and 1 in-frame indel) in 9 of the 15 preselected focal epilepsy genes in 16/112 patients. Six of these VUSs were singletons (ie, absent from gnomAD). The reported VUSs are listed in table 3.

#### Rare variants in NAFE candidate genes

Using an extended exome-wide screen for rare non-synonymous variants, we identified six rare missense variants with damaging

in silico prediction in four candidate genes for NAFE with existing but so far only limited evidence for a disease association. This included variants in the genes MTOR (2×), KCNA2 (2×), RBFOX1 (1×) and SCN3A (1×). Details about the prioritised candidate variants are displayed in table 4.

Considering all genetic variants reported in this study (including diagnostic variants, VUSs and candidate variants), 31/112 patients (28%) carried at least one variant.

# Multiple rare variants

When also accounting for VUSs and prioritised candidate variants, 5 of 112 patients had double hits in different epilepsy genes. Two of these patients carried one pathogenic variant and one VUS (DEPDC5/RELN and NPRL3/SCN2A), and one patient harboured two VUSs in focal epilepsy genes (LGI1/NPRL3). However, this patient had familial lateral TLE with auditory auras, primarily suggesting a pathogenic role of the LGI1 variant given the characteristic phenotypic constellation. Two further patients each had one VUS and one candidate variant (DEPD-C5/SCN3A and RELN/KCNA2).

A comprehensive list including all rare variants with a MAF of <0.01% detected in our cohort is provided in online supplementary table S2.

#### DISCUSSION

Over the past few years, large-scale sequencing studies have convincingly demonstrated a burden of rare variants in non-lesional epilepsies, including NAFE.<sup>7-9</sup> In spite of this rapid progress, it is still unclear how the emerging knowledge derived from such studies can be translated into the clinical–diagnostic setting. Previous studies evaluating the diagnostic use of NGS were primarily performed in clinically heterogeneous cohorts, often with concomitant syndromic features.<sup>10-13</sup> In contrast, there is still a remarkable lack of data addressing the clinical application of NGS for the more common non-lesional epilepsies, of which NAFE is the one most frequently encountered in adult epileptology. To fill this gap, we analysed 112 exomes of well-phenotyped patients with NAFE, aiming to provide a clinical–genetic diagnosis.

Using a broad exome-based approach, we identified molecular diagnoses in 12%, which is less than in syndromic epilepsies, <sup>13</sup> but comparable to the small-scale study by Perucca *et al* evaluating diagnostic ES with targeted gene analysis in NAFE. <sup>14</sup> In contrast, our diagnostic yield is remarkably higher than that reported by Hildebrand *et al* and Tsai *et al*, who found diagnostic variants in only 0.8% and 1.85% of cases, respectively. <sup>15</sup> <sup>16</sup> First, the lower hit rate may be explained by the broader inclusion criteria of these studies, not accounting for age of onset and a positive family history. Second, phenotyping was less accurate; for example, some patients did not receive an MRI scan prior to inclusion. Moreover, they did not include CNVs and in-frame indels, which may also play a role in NAFE. The lower diagnostic yield may also partly be explained by the fact that these two studies only included *DEPDC5*, but not *NPRL2* and *NPRL3* in their analyses. <sup>15</sup> <sup>16</sup>

Of note, two pathogenic microdeletions were detected in our study, highlighting that monogenic CNVs should also be considered. This is a strong argument in favour of diagnostic approaches combining SNV and CNV analysis. While playing an acknowledged role in the severe infantile epilepsies with comorbid features, we point out that the monogenic role of CNVs in NAFE is probably underestimated.<sup>29</sup>

J Med Genet: first published as 10.1136/jmedgenet-2019-106658 on 21 February 2020. Downloaded from http://jmg.bmj.com/ on April 10, 2024 by guest. Protected by copyright.

Variant classification												
Vari	۵.	<u> </u>	*d	۵	۵	<b>*</b>	<u>~</u>	<u>*</u>	۵	۵	4	۵.
Allele 2 frequency (gnomAD)	0	0	0	0	0	0.000004	0	0.000004	N/A	0	0	N/A
In silico (CADD, pph2 and SIFT)	N/A	33, D, D	33, D, D	35, N/A	N/A	16.9, B, T	39, N/A	29.9, PD, T	N/A	35, D, D	25.8, N/A	N/A
Gene (transcript) variants	DEPDC5 NM_001242896.1: c.4131delC p.(Ser1379LeufsTer2)	<i>GABRG2</i> NM_198903.2: c.1087C>T p.(Arg363Tp)	NPRL3 NM_001077350.2: c.905C>T p.(Pro302Leu)	<i>DEPDC5</i> NM_001242896.1: c.381T>A p.(Tyr127Ter)	<i>DEPDC5</i> NM_001242896.1: c.4297dupG p.(Asp1433GlyfsTer26)	<i>DEPDC5</i> NM_001242896.1: c.1526G>T p.(Arg509Leu)	DEPDC5 NM_001242896.1: c.1459C>T p.(Arg487Ter)	DEPDC5 NM_001242896.1: c.274C>T p.(Pro92Ser)	3 Mb microdeletion Xq21.33-q22.1 (involving <i>PCDH19</i> ) chrX:96684649- 99663594	SCN1A NM_001165963.1: c.4786C>T; p.(Arg1596Cys)	<i>STX18</i> NM_052874.3: c.537+1G>A	380kb microdeletion 16p13.3 (involving <i>NPRL3</i> ) chr16:97 430–4 76 719
Family history	Father and aunt with seizures	Negative	Sister and paternal aunt with focal epilepsy	Sister with FLE. paternal grandfather and great aunt with epilepsy	Brother with epilepsy since age of 4 years	Father with seizures	Negative	Mother and maternal uncle with epilepsy	Negative	Negative	Negative	Negative
Treatment response (ILAE criteria) <sup>16</sup>	Resistant	Undefined	Resistant	Undefined	Resistant	Resistant	Resistant	Undefined	Resistant	Resistant	Resistant	Resistant
AED trials	LEV and OXC	VPA, PRM, TPM and LEV	PRG, LTG, CBZ and ZNS	OXC	LEV, ZNS, CBZ, TPM, GBP and PRG	CBZ, LEV, OXC, PHT, VPA, LTG, GBP and anteromedial TL resection	LEV, OXC, LCM	VPA, LEV and PRG	TPM, CBZ, LCM, LTG, LEV, VGB and VPA	LEV, LCM, OXC, FBM and VPA	VPA, LCM, BRV, ESL, PER, CBZ, PRM, OXC, LTG, anteromedial TL resection (right), DBS implant	CBZ, LEV and TPM
Epilepsy syndrome	OLE	OLE	FLE	FLE	TLE	TLE	TE	J.	FLE	FLE	<u>=</u>	UE
MRI	Normal	Normal	Normal	Normal	Normal	Left HS	Normal	Normal	Normal	Normal	Normal	Normal
EEG	lctal: right occipital Interictal: right temporal	Ictal: subclinical occipital (left>right) Interictal: generalised	lctal: bilateral frontal Interictal: no changes	Ictal: left frontal Interictal: left frontal	Ictal: right temporal Interictal: bitemporal	Ictal: left temporal Interictal: left temporal	Ictal: left temporal Interictal: left temporal	Ictal: bilateral Interictal: bitemporal spikes (left>right)	Ictal: not recorded Interictal: left frontal	lctal: not recorded Interictal: left frontal	ictal: right temporal Interictal: bitemporal	Ictal: right hemispheric Interictal: right frontotemporal spikes
Seizure type	Aura with vertigo, dark shadows, sees flashing lights (phosphene), partially followed by impaired consciousness, motionless stare, oral and bilateral hand automatisms	Focal impaired awareness seizures (motionless stare, feeling of blackening out), BTCS	Aura with fear, hyperkinetic seizures at night, behavioural arrest, tonic elevation of right leg, BTCS (daily seizures)	Nocturnal hyperkinetic seizures, restlessness, postictal aphasia	Dystonic posturing of both arms, BTCS, postictal agitation (frequency 5/month)	Nocturnal seizures with motionless stare, hand automatisms (right), postictal nose wiping (left)	Behavioural arrest, speech arrest, postictal motor aphasia, rarely BTCS	Epigastric aura, jamais vu, oral automatisms, vocalisation, tonic posturing of both arms (4/ month), nocturnal BTCS (1–2/month)	Auras with nausea, hypersalivation, vomiting, visual/auditory hallucinations, motionless stare, facial twitching, BTCS (1/year)	Focal seizures with visual field restriction, gaze deviation, eyelid twitching, confusion, BTCS	Auras with vertigo, impaired consciousness, motionless stare, BTCS	Nocturnal seizures with awakening, hypermotor seizures, oral automatisms, bilateral hand automatisms, vocalisation, amnesia, postictal confusion (several seizures per week)
Age at onset (years)	32	m	-	1	19	36	-	6	2	е	6	10
Sex	4-	4-	<del></del>	<del></del>	E	<del>-</del>	E	E	<del>-</del>	<del></del>	E	E
Patient number	12	41	24	25	27	32	43	51	56	72	17	18

Table 2

Detailed clinical characterisation of all patients with diagnostic variants in known epilepsy genes

Table 2	0	Table 2 Continued											
Patient number	Sex	Age at Agient onset number Sex (years)	Seizure type	EEG	MRI	Epilepsy syndrome	pilepsy syndrome AED trials	Treatment response (ILAE criteria) <sup>16</sup> F	Family history	Gene (transcript) variants	In silico (CADD, pph; and SIFT)	In silico Allele (CADD, pph2 frequency and SIFT) (gnomAD)	Variant classification
108	E	en en	Head version (changing sides), elevation/ Ictal: not localisable extension left arm, flexion of right arm (figure Interictal: no changes of 4 sign), postictal aphasia, alexia and paresis of right arm, postictal nose wiping, BTCS	Ictal: not localisable Interictal: no changes	Normal	丑	PHT, LEV, LCM, RUF, ZNS, CBZ, VPA, LTG, PER, VGB, PRM and DBS implant	Resistant	Negative	NPR13 NM_001077350.2: c.898C>T p.(Gln300Ter)	39, N/A	0	۵

bilateral toric-clonic seizure; CADD, combined annotation-dependent depletion; CBZ, Carbamazepine; DBS, deep brain stimulation; EEG, electroencephalogram; ESL, Eslicabazepine acetate; f, female; FLE, frontal lobe epilepsy; GBP, Gabapentin; Against Epilepsy; LCM, Lacosamide; LEV, Levetiracetam; LP, likely pathogenic; LTG, Lamortrigin; m, male; NIA, not applicable; OLE, occipital lobe epilepsy; OXC, Oxcarbazepine; P, pathogenic; PER, Perampanel; PHT, Phenytoin; pph2, PolyPhen-2 (8, benign; D, PRM, Primidone; RUF, Rufinamide; SIFT, sorting intolerant from AED, antiepileptic drug; BRV, Brivaracetam; BTCS, gnomAD, Genome Aggregation

r damaging; PD, possibly damaging); PRG, Pregabalin ant (T, tolerated; D, deleterious); TL, temporal lobe l epilepsy; VGB, Vigabatrin; VPA, Valproic acid; VUS, variant of uncertain significance; ZNS, Zonisamide.

In line with previous NGS data, our results demonstrate the implication of a few common genes and a much greater number of rarely mutated genes in the aetiology of NAFE with undistinguishable phenotypes.<sup>30</sup> Four of the 13 pathogenic variants were detected in genes with previously no robust evidence for an association with NAFE. However, recent data have suggested that NAFE is also part of the phenotypic spectrum of STX1B and GABRG2 that were previously associated with more severe generalised epilepsies and developmental and epileptic encephalopathies (DEEs). 31 32 We hypothesise that in our study, these cases possibly represent phenocopies, since also generalised EEG changes were documented in the patient carrying the GABRG2 variant, and the histological workup eventually revealed an mMCD in the patient with the STX1B variant. This exemplifies the inability to predict the causative genetic defect by the phenotype alone, which is a strong argument in favour of broad genomic testing early in the diagnostic pathway. Given the significant correlation between age at onset and a molecular diagnosis. patients with early-onset NAFE may preferentially be selected. In contrast, somewhat surprisingly, our data (in line with the findings of Perucca et al)14 do not support a positive family history alone as a reliable predictive marker for a genetic diagnosis.

Some of the genetically solved cases in our cohort demonstrate that a molecular diagnosis may have direct management implications for the patients. Despite the genetic heterogeneity, almost 70% of diagnostic hits were detected in genes of the GATOR1 complex (formed by DEPDC5, NPRL2 and NPRL3), pointing towards a major role of the mTOR signalling pathway in the pathogenesis of NAFE. GATOR1 normally suppresses mTOR signalling, so that haploinsufficiency in turn results in mTOR hyperactivation.<sup>33</sup> The decisive role of the mTOR pathway is particularly interesting, as pharmacological mTOR inhibition (eg, by everolimus) might specifically be beneficial for this patient population usually characterised by a high rate of AED resistance.<sup>34</sup> Furthermore, as opposed to other genetic (eg. SCNA1-related) epilepsies, there is at least anecdotal evidence that these patients may achieve satisfactory seizure outcome following epilepsy surgery.<sup>35</sup> These observations together give rise to the hope that effective personalised treatment approaches may become available for this difficult-to-treat patient group. Another example with the potential for a genotype-guided treatment option is the patient with a pathogenic SCN1A variant who did not respond to oxcarbazepine treatment. Having a precise genetic diagnosis at hand after genetic testing, there is now a rational argument to avoid sodium channel blockers.

Apart from diagnostic variants, we found a high rate of VUSs in established focal epilepsy genes and rare deleterious missense variants in four candidate genes (MTOR, KCNA2, RBFOX1 and SCN3A) that have already been associated with NAFE, but for which evidence is limited. 36-39 Though not formally classifiable as pathogenic in a diagnostic report, it can be presumed that at least some of these variants are indeed disease relevant (in a monogenic sense). As exemplified by our study, collating wellcharacterised phenotypes and variants is essential to reveal the clinical significance of genetic defects and to elucidate genotype-phenotype correlations in a stepwise manner. The ongoing expansion of gene discoveries and known variants as well as a periodic reanalysis of exome data have the potential to enhance the diagnostic outcomes in coming years.<sup>41</sup>

One noteworthy factor possibly limiting the diagnostic yield in our study is the lack of family genotype data, which are useful to confirm segregation in familial cases or de novo mutagenesis in sporadic cases. However, it is widely accepted that the penetrance of variants in epilepsies is often incomplete, meaning

# Neurogenetics

Patient ID, sex, age at onset (years)	Epilepsy phenotype	Gene (transcript) variants	In silico (CADD, pph2 and SIFT)	Allele frequency (gnomAD)
1, f, 6	MRI-negative TLE	<i>LGI1</i> NM_005097.3: c.1208G>A p.(Ser403Asn)	25.5, D, D	0
		NPRL3 NM_001077350.2: c.1561G>A p.(Ala521Thr)	24.7, D, T	0.00002
7, f, 1	MRI-negative TLE	SCN8A NM_014191.3: c.3185A>C p.(Asn1062Thr)	23.6, PD, D	0
19, f, 12	MRI-negative TLE	<i>LGI1</i> NM_005097.2: c.1124C>T p.(Ala375Val)	20.2, B, T	0.000018
31, f, 3	MRI-negative FLE	CHRNA4 NM_000744.6: c.419A>G p.(Lys140Arg)	25.1, D, D	0
43, m, 1	MRI-negative TLE	RELN NM_005045.3: c.3479A>G p.(Asn1160Ser)	23.6, D, D	0.000007
49, f, 10	MRI-negative FLE	KCNT1 NM_020822.2: c.2061_2066delCGGTGG p.(Gly691_Gly692del)	N/A (indel)	0.000034
50, f, 54	MRI-negative TLE	KCNQ3 NM_004519.3: c.1709T>C p.(Met570Thr)	23.7, PD, D	0.000024
55, m, 14	MRI-negative TLE	NPRL3 NM_001077350.2: c.745G>A p.(Glu249Lys)	35, D, T	0.000099
61, f, 49	MRI-negative TLE	KCNQ3 NM_004519.3: c.2237C>T p.(Thr746Met)	23.2, D, D	0.000035
70, m, 18	MRI-negative TLE	RELN NM_005045.3: c.1795C>T p.(Arg599Cys)	34, PD, D	0.000028
84, m, 7	MRI-negative FLE	RELN NM_005045.3: c.8492C>T p.(Pro2831Leu)	21.9, D, T	0.000036
90, m, 34	MRI-negative TLE	DEPDC5 NM_001242896.1: c.1526G>A p.(Arg509His)	23.6, D, T	0.000036
91, f, 13	MRI-negative FLE	DEPDC5 NM_001242896.1: c.3521C>T p.(Ser1174Phe)	27.8, PD, D	0
101, m, 23	MRI-negative UFE	NPRL3 NM_001077350.2: c.1053G>C p.(Gln351His)	20.3, B, T	0
108, m, 3	MRI-negative FLE	SCN2A NM_021007.2: c.3545G>A p.(Cys1182Tyr)	29.2, PD, D	0

Table 3 Continued				
Patient ID, sex, age at onset (years)	Epilepsy phenotype	Gene (transcript) variants	In silico (CADD, pph2 and SIFT)	Allele frequency (gnomAD)
110, f, 15	HS/HA-TLE	RELN NM_005045.3: c.10210C>T p.(Arg3404Cys)	35, D, T	0.000012

Patients with multiple rare variants are highlighted in grey.

CADD, combined annotation-dependent depletion; f, female; FLE, frontal lobe epilepsy; gnomAD, Genome Aggregation Database; HA, hippocampal atrophy; HS, hippocampal sclerosis; m, male; N/A, not applicable; pph2, PolyPhen-2 (B, benign; D, probably damaging; PD. possibly damaging); SIFT, sorting intolerant from tolerant (D, deleterious; T, tolerated); TLE, temporal lobe epilepsy; UFE, unclassified focal epilepsy.

Prioritised candidate variants in genes with anecdotal evidence for an association with non-acquired focal epilepsy Patient ID, sex, age at onset (years) **Epilepsy phenotype** Gene (transcript) variants In silico (CADD, pph2 and SIFT) Allele frequency (gnomAD) 13, f, 3 RBFOX1 HS/HA-TLE 35. 0.000012 NM 145891.2: D, T c.1013G>A p.(Arg338His) KCNA2 47, m, 15 MRI-negative UFE 32, D, D 0.000003976 NM 004974.3: c.128G>A p.(Arg43Gln) 52, f, 5 MRI-negative TLE MTOR 28.2, PD, T 0.00001194 NM 004958.3: c.2069C>T p.(Ala690Val) 90, m, 34 MRI-negative TLE SCN3A 27.3, D, D 0.000003977 NM\_001081676.1: c.770G>A p.(Cys257Tyr) 92, f, 14 MRI-negative UFE MTOR 35, D, D NM 004958.3 c.6649C>T p.(Arg2217Trp) 110, f, 15 HS/HA-TLE KCNA2 25.5, D, D NM 004974.3: c.209A>T p.(Asp70Val)

Patients with multiple rare variants are highlighted in grey.

AED, antiepileptic drug; CADD, combined annotation-dependent depletion; f, female; gnomAD, Genome Aggregation Database; HA, hippocampal atrophy; HS, hippocampal sclerosis; m, male; N/A, not applicable; OLE, occipital lobe epilepsy; pph2, PolyPhen-2 (B, benign; D, probably damaging; PD, possibly damaging); SIFT, sorting intolerant from tolerant (D, deleterious; T, tolerated); TLE, temporal lobe epilepsy; UFE, unclassified focal epilepsy; VUS, variant of uncertain significance.

that the presence of a variant in a healthy family member does not necessarily exclude disease causation. The exact reason for this phenomenon is still poorly understood but may in part be due to multiple superimposed genetic variants contributing to disease causation in an oligogenic framework. As illustrative examples, we found genetic double hits (including diagnostic variants, VUSs and candidate variants) in five different patients. Acknowledging that this observation is purely explorative and therefore not sufficient to prove an oligogenic or digenic effect, we consider that multiple rare variants may act a part in epileptogenesis. Yet, this hypothesis requires larger sample sizes and functional investigations for confirmation.

Taken together, our data underscore a considerable but heterogeneous genetic contribution to NAFE with GATOR1 complex genes representing the by far most common monogenic aetiology identified to date. Although the diagnostic yield is relatively low compared with early-infantile phenotypes, the high rate of VUSs and emerging candidate aetiologies suggest that outcomes may improve, along with the constantly expanding knowledge. In view of the increased availability of genotype-guided individualised treatments (particularly for GATOR1/mTOR-related epilepsies), ES constitutes a promising diagnostic tool also for this patient population.

**Acknowledgements** All authors thank the patients for participating in the study. MK also thanks the Austrian Society of Neurology and the Austrian Society of Epileptology, which supported him with a 6-month research fellowship.

**Contributors** FZ designed and supervised the study. MK analysed exome data and wrote the manuscript. TM supervised the genetic analyses. TMS was responsible for the bioinformatic pipeline. MW and AZ were involved in genetic data analysis. CH was responsible for DNA preparation and quality check. EG, SW and BL-D were involved in the sequencing pipeline. TB was responsible for the secondary confirmation of copy number variants. GK re-evaluated patient MRIs. EP, SA-W and ES were involved in the clinical diagnosis of patients.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

**Ethics approval** The study was approved by the ethics committee of the Medical University of Vienna (ethics approval number: 2051/2016).

**Provenance and peer review** Not commissioned; externally peer reviewed.

#### ORCID iD

Martin Krenn http://orcid.org/0000-0003-3026-3082

#### **REFERENCES**

1 Banerjee PN, Filippi D, Allen Hauser W. The descriptive epidemiology of epilepsy-a review. Epilepsy Res 2009;85:31–45.

# **Neurogenetics**

- 2 Nguyen DK, Mbacfou MT, Nguyen DB, Lassonde M. Prevalence of nonlesional focal epilepsy in an adult epilepsy clinic. Can J Neurol Sci 2013;40:198–202.
- 3 Thomas RH, Berkovic SF. The hidden genetics of epilepsy-a clinically important new paradigm. *Nat Rev Neurol* 2014;10:283–92.
- 4 Steinlein OK, Mulley JC, Propping P, Wallace RH, Phillips HA, Sutherland GR, Scheffer IE, Berkovic SF. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. *Nat Genet* 1995;11:201–3.
- 5 Dibbens LM, de Vries B, Donatello S, Heron SE, Hodgson BL, Chintawar S, Crompton DE, Hughes JN, Bellows ST, Klein KM, Callenbach PMC, Corbett MA, Gardner AE, Kivity S, Iona X, Regan BM, Weller CM, Crimmins D, O'Brien TJ, Guerrero-López R, Mulley JC, Dubeau F, Licchetta L, Bisulli F, Cossette P, Thomas PQ, Gecz J, Serratosa J, Brouwer OF, Andermann F, Andermann E, van den Maagdenberg AMJM, Pandolfo M, Berkovic SF, Scheffer IE. Mutations in DEPDC5 cause familial focal epilepsy with variable foci. Nat Genet 2013;45:546–51.
- 6 Ricos MG, Hodgson BL, Pippucci T, Saidin A, Ong YS, Heron SE, Licchetta L, Bisulli F, Bayly MA, Hughes J, Baldassari S, Palombo F, Santucci M, Meletti S, Berkovic SF, Rubboli G, Thomas PQ, Scheffer IE, Tinuper P, Geoghegan J, Schreiber AW, Dibbens LM, Epilepsy Electroclinical Study Group. Mutations in the mammalian target of rapamycin pathway regulators NPRL2 and NPRL3 cause focal epilepsy. Ann Neurol 2016;79:120–31.
- 7 Epi4K consortium, Epilepsy Phenome/Genome ProjectAllen AS, Bellows ST, Berkovic SF, Bridgers J, Burgess R, Cavalleri G, Chung S-K, Cossette P, Delanty N, Dlugos D, Epstein MP, Freyer C, Goldstein DB, Heinzen EL, Hildebrand MS, Johnson MR, Kuzniecky R, Lowenstein DH, Marson AG, Mayeux R, Mebane C, Mefford HC, O'Brien TJ, Ottman R, Petrou S, Petrovski S, Pickrell WO, Poduri A, Radtke RA, Rees MI, Regan BM, Ren Z, Scheffer IE, Sills GJ, Thomas RH, Wang Q, Abou-Khalil B, Alldredge BK, Amrom D, Andermann E, Andermann F, Bautista JF, Berkovic SF, Bluvstein J, Boro A, Cascino GD, Consalvo D, Crumrine P, Devinsky O, Dlugos D, Epstein MP, Fiol M, Fountain NB, French J, Freyer C, Friedman D, Geller EB, Glauser T, Glynn S, Haas K, Haut SR, Hayward J, Helmers SL, Joshi S, Kanner A, Kirsch HE, Knowlton RC, Kossoff EH, Kuperman R, Kuzniecky R, Lowenstein DH, Motika PV, Novotny EJ, Ottman R, Paolicchi JM, Parent JM, Park K, Poduri A, Sadieir LG, Scheffer IE, Shellhaas RA, Sherr EH, Shih JJ, Shinnar S, Singh RK, Sirven J, Smith MC, Sullivan J, Thio LL, Venkat A, Vining EPG, Von Allmen GK, Weisenberg JL, Widdess-Walsh P, Winawer MR. Ultra-rare genetic variation in common epilepsies: a case-control sequencing study. *Lancet Neurol* 2017;16:135–43.
- 8 May P, Girard S, Harrer M, Bobbili DR, Schubert J, Wolking S, Becker F, Lachance-Touchette P, Meloche C, Gravel M, Niturad CE, Knaus J, De Kovel C, Toliat M, Polvi A, Iacomino M, Guerrero-López R, Baulac S, Marini C, Thiele H, Altmüller J, Jabbari K, Ruppert A-K, Jurkowski W, Lal D, Rusconi R, Cestèle S, Terragni B, Coombs ID, Reid CA, Striano P, Caglayan H, Siren A, Everett K, Møller RS, Hjalgrim H, Muhle H, Helbig I, Kunz WS, Weber YG, Weckhuysen S, Jonghe PD, Sisodiya SM, Nabbout R, Franceschetti S, Coppola A, Vari MS, Kasteleijn-Nolst Trenité D, Baykan B, Ozbek U, Bebek N, Klein KM, Rosenow F, Nguyen DK, Dubeau F, Carmant L, Lortie A, Desbiens R, Clément J-F, Cieuta-Walti C, Sills GJ, Auce P, Francis B, Johnson MR, Marson AG, Berghuis B, Sander JW, Avbersek A, McCormack M, Cavalleri GL, Delanty N, Depondt C, Krenn M, Zimprich F, Peter S, Nikanorova M, Kraaij R, van Rooij J, Balling R, Ikram MA, Uitterlinden AG, Avanzini G, Schorge S, Petrou S, Mantegazza M, Sander T, LeGuern E, Serratosa JM, Koeleman BPC, Palotie A, Lehesjoki A-E, Nothnagel M, Nürnberg P, Maljevic S, Zara F, Cossette P, Krause R, Lerche H, May P, Girard S, Harrer M, Bobbili DR, Schubert J, Wolking S, Becker F, Lachance-Touchette P, Meloche C, Gravel M, Niturad CE, Knaus J, De Kovel C, Toliat M, Polvi A, Iacomino M, Guerrero-López R, Baulac S, Marini C, Thiele H, Altmüller J, Jabbari K, Ruppert A-K, Jurkowski W, Lal D, Rusconi R, Cestèle S, Terragni B, Coombs ID, Reid CA, Striano P, Caglayan H, Siren A, Everett K, Møller RS, Hjalgrim H, Muhle H, Helbig I, Kunz WS, Weber YG, Weckhuysen S, De Jonghe P, Sisodiya SM, Nabbout R, Franceschetti S, Coppola A, Vari MS, Kasteleijn-Nolst Trenité D, Baykan B, Ozbek U, Bebek N, Klein KM, Rosenow F, Nguyen DK, Dubeau F, Carmant L, Lortie A, Desbiens R, Clément J-F, Cieuta-Walti C, Sills GJ. Auce P. Francis B. Johnson MR. Marson AG. Berghuis B. Sander JW. Avbersek A, McCormack M, Cavalleri GL, Delanty N, Depondt C, Krenn M, Zimprich F, Peter S, Nikanorova M, Kraaij R, van Rooij J, Balling R, Arfan Ikram M, Uitterlinden AG, Avanzini G, Schorge S, Petrou S, Mantegazza M, Sander T, LeGuern E, Serratosa JM, Koeleman BPC, Palotie A, Lehesjoki A-E, Nothnagel M, Nürnberg P, Maljevic S, Zara F, Cossette P, Krause R, Lerche H, Ferlazzo E, di Bonaventura C, La Neve A, Tinuper P, Bisulli F, Vignoli A, Capovilla G, Crichiutti G, Gambardella A, Belcastro V, Bianchi A, Yalçın D, Dizdarer G, Arslan K, Yapıcı Z, Kuşcu D, Leu C, Heggeli K, Willis J, Langley SR, Jorgensen A, Srivastava P, Rau S, Hengsbach C, Sonsma ACM, Becker F, Toliat M, Polvi A, Iacomino M, Guerrero-López R, Marini C, Altmüller J, Ruppert A-K, Rusconi R, Cestèle S, Terragni B, Coombs ID, Reid CA, Striano P, Caglayan H, Siren A, Everett K, Møller RS, Hjalgrim H, Helbig I, Weber YG, De Jonghe P, Nabbout R, Franceschetti S, Vari MS, Trenité DK-N, Baykan B, Ozbek U, Klein KM, Rosenow F, Carmant L, Lortie A, Desbiens R, Clément J-F, Cieuta-Walti C, Sills GJ, Ben Francis SJW, Avbersek A, McCormack M, Peter S, Nikanorova M, Kraaij R, van Rooij J, Balling R, Ikram MA, Uitterlinden AG, Avanzini G, Schorge S, Petrou S, Mantegazza M, Sander T, Palotie A, Lehesjoki A-E, Maljevic S, Zara F, Cossette P, Lerche H, May P, Trenité DK-N, Ben Francis JMR, Consortium E, Consortium EC, Consortium E, Epicure Consortium, EuroEPINOMICS CoGIE Consortium, EpiPGX Consortium. Rare coding variants in

- genes encoding GAB<sub>AA</sub> receptors in genetic generalised epilepsies: an exome-based case-control study. *Lancet Neurol* 2018;17:699–708.
- 9 Epi25 Collaborative. Electronic address: s.berkovic@unimelb.edu.au, Epi25 CollaborativeFeng Y-CA, Howrigan DP, Abbott LE, Tashman K, Cerrato F, Singh T, Heyne H, Byrnes A, Churchhouse C, Watts N, Solomonson M, Lal D, Heinzen EL, Dhindsa RS. Stanley KE, Cavalleri GL, Hakonarson H, Helbig I, Krause R, May P, Weckhuysen S, Petrovski S, Kamalakaran S, Sisodiya SM, Cossette P, Cotsapas C, De Jonghe P, Dixon-Salazar T, Guerrini R, Kwan P, Marson AG, Stewart R, Depondt C, Dlugos DJ, Scheffer IE, Striano P, Freyer C, McKenna K, Regan BM, Bellows ST, Leu C, Bennett CA, Johns EMC, Macdonald A, Shilling H, Burgess R, Weckhuysen D, Bahlo M, O'Brien TJ, Todaro M, Stamberger H, Andrade DM, Sadoway TR, Mo K, Krestel H, Gallati S, Papacostas SS, Kousiappa I, Tanteles GA, těrbová K, Vlčková M, Sedláčková L, Laššuthová P, Klein KM, Rosenow F, Reif PS, Knake S, Kunz WS, Zsurka G, Elger CE, Bauer J, Rademacher M, Pendziwiat M, Muhle H, Rademacher A, van Baalen A, von Spiczak S, Stephani U, Afawi Z, Korczyn AD, Kanaan M, Canavati C, Kurlemann G, Müller-Schlüter K, Kluger G, Häusler M, Blatt I, Lemke JR, Krey I, Weber YG, Wolking S, Becker F, Hengsbach C, Rau S, Maisch AF, Steinhoff BJ, Schulze-Bonhage A, Schubert-Bast S, Schreiber H, Borggräfe I, Schankin CJ, Mayer T, Korinthenberg R, Brockmann K, Kurlemann G, Dennig D, Madeleyn R, Kälviäinen R, Auvinen P, Saarela A, Linnankivi T, Lehesjoki A-E, Rees MI, Chung S-K, Pickrell WO, Powell R, Schneider N, Balestrini S, Zagaglia S, Braatz V, Johnson MR, Auce P, Sills GJ, Baum LW, Sham PC, Cherny SS, Lui CHT, Barišić N, Delanty N, Doherty CP, Shukralla A, McCormack M, El-Naggar H, Canafoglia L, Franceschetti S, Castellotti B, Granata T, Zara F, Iacomino M, Madia F, Vari MS, Mancardi MM, Salpietro V, Bisulli F, Tinuper P, Licchetta L, Pippucci T, Stipa C, Minardi R, Gambardella A, Labate A, Annesi G, Manna L, Gagliardi M, Parrini E, Mei D, Vetro A, Bianchini C, Montomoli M, Doccini V, Marini C, Suzuki T, Inoue Y, Yamakawa K, Tumiene B, Sadleir LG, King C, Mountier E, Caglayan SH, Arslan M, Yapıcı Z, Yis U, Topaloglu P, Kara B, Turkdogan D, Gundogdu-Eken A, Bebek N, Uğur-İşeri S, Baykan B, Salman B, Haryanyan G, Yücesan E, Kesim Y, Özkara Çiğdem, Poduri A, Shiedley BR, Shain C, Buono RJ, Ferraro TN, Sperling MR, Lo W, Privitera M, French JA, Schachter S, Kuzniecky RI, Devinsky O, Hegde M, Khankhanian P, Helbig KL, Ellis CA, Spalletta G, Piras F, Piras F, Gili T, Ciullo V, Reif A, McQuillin A, Bass N, McIntosh A, Blackwood D, Johnstone M, Palotie A, Pato MT, Pato CN, Bromet EJ, Carvalho CB, Achtyes ED, Azevedo MH, Kotov R, Lehrer DS, Malaspina D, Marder SR, Medeiros H, Morley CP, Perkins DO, Sobell JL, Buckley PF, Macciardi F, Rapaport MH, Knowles JA, Fanous AH, McCarroll SA, Gupta N, Gabriel SB, Daly MJ, Lander ES, Lowenstein DH, Goldstein DB, Lerche H, Berkovic SF, Neale BM. Ultra-Rare genetic variation in the epilepsies: a whole-exome sequencing study of 17,606 individuals. Am J Hum Genet 2019:105:267-82.
- 10 Lemke JR, Riesch E, Scheurenbrand T, Schubach M, Wilhelm C, Steiner I, Hansen J, Courage C, Gallati S, Bürki S, Strozzi S, Simonetti BG, Grunt S, Steinlin M, Alber M, Wolff M, Klopstock T, Prott EC, Lorenz R, Spaich C, Rona S, Lakshminarasimhan M, Kröll J, Dorn T, Krämer G, Synofzik M, Becker F, Weber YG, Lerche H, Böhm D, Biskup S. Targeted next generation sequencing as a diagnostic tool in epileptic disorders. *Epilepsia* 2012;53:1387–98.
- 11 Helbig KL, Farwell Hagman KD, Shinde DN, Mroske C, Powis Z, Li S, Tang S, Helbig I. Diagnostic exome sequencing provides a molecular diagnosis for a significant proportion of patients with epilepsy. *Genet Med* 2016;18:898–905.
- 12 Lindy AS, Stosser MB, Butler E, Downtain-Pickersgill C, Shanmugham A, Retterer K, Brandt T, Richard G, McKnight DA. Diagnostic outcomes for genetic testing of 70 genes in 8565 patients with epilepsy and neurodevelopmental disorders. *Epilepsia* 2018;59:1062–71.
- 13 Snoeijen-Schouwenaars FM, van Ool JS, Verhoeven JS, van Mierlo P, Braakman HMH, Smeets EE, Nicolai J, Schoots J, Teunissen MWA, Rouhl RPW, Tan IY, Yntema HG, Brunner HG, Pfundt R, Stegmann AP, Kamsteeg E-J, Schelhaas HJ, Willemsen MH. Diagnostic exome sequencing in 100 consecutive patients with both epilepsy and intellectual disability. *Epilepsia* 2019;60:155–64.
- 14 Perucca P, Scheffer IE, Harvey AS, James PA, Lunke S, Thorne N, Gaff C, Regan BM, Damiano JA, Hildebrand MS, Berkovic SF, O'Brien TJ, Kwan P. Real-World utility of whole exome sequencing with targeted gene analysis for focal epilepsy. *Epilepsy Res* 2017:131:1–8.
- 15 Hildebrand MS, Myers CT, Carvill GL, Regan BM, Damiano JA, Mullen SA, Newton MR, Nair U, Gazina EV, Milligan CJ, Reid CA, Petrou S, Scheffer IE, Berkovic SF, Mefford HC. A targeted resequencing gene panel for focal epilepsy. *Neurology* 2016:86:1605–12.
- 16 Tsai M-H, Chan C-K, Chang Y-C, Lin C-H, Liou C-W, Chang W-N, Ng C-C, Lim K-S, Hwang D-Y. Molecular genetic characterization of patients with focal epilepsy using a customized targeted resequencing gene panel. Front Neurol 2018;9:1–9.
- 17 Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshé SL, Perucca E, Wiebe S, French J. Definition of drug resistant epilepsy: consensus proposal by the AD hoc Task force of the ILAE Commission on therapeutic strategies. *Epilepsia* 2010:51:1069–77.
- 18 Kremer LS, Bader DM, Mertes C, Kopajtich R, Pichler G, Iuso A, Haack TB, Graf E, Schwarzmayr T, Terrile C, Koňaříková E, Repp B, Kastenmüller G, Adamski J, Lichtner P, Leonhardt C, Funalot B, Donati A, Tiranti V, Lombes A, Jardel C, Gläser D, Taylor RW, Ghezzi D, Mayr JA, Rötig A, Freisinger P, Distelmaier F, Strom TM, Meitinger T, Gagneur J, Prokisch H. Genetic diagnosis of Mendelian disorders via RNA sequencing. Nat Commun 2017;8:15824.

- 19 Plagnol V, Curtis J, Epstein M, Mok KY, Stebbings E, Grigoriadou S, Wood NW, Hambleton S, Burns SO, Thrasher AJ, Kumararatne D, Doffinger R, Nejentsev S. A robust model for read count data in exome sequencing experiments and implications for copy number variant calling. *Bioinformatics* 2012;28:2747–54.
- 20 Ye K, Schulz MH, Long Q, Apweiler R, Ning Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. *Bioinformatics* 2009;25:2865–71.
- 21 Perucca P. Genetics of focal epilepsies: what do we know and where are we heading? *Epilepsy Curr* 2018;18:356–62.
- 22 Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of medical genetics and genomics and the association for molecular pathology. *Genet Med* 2015;17:405–23.
- 23 Jagadeesh KA, Wenger AM, Berger MJ, Guturu H, Stenson PD, Cooper DN, Bernstein JA, Bejerano G. M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity. *Nat Genet* 2016;48:1581–6.
- 24 Baldassari S, Picard F, Verbeek NE, van Kempen M, Brilstra EH, Lesca G, Conti V, Guerrini R, Bisulli F, Licchetta L, Pippucci T, Tinuper P, Hirsch E, de Saint Martin A, Chelly J, Rudolf G, Chipaux M, Ferrand-Sorbets S, Dorfmüller G, Sisodiya S, Balestrini S, Schoeler N, Hernandez-Hernandez L, Krithika S, Oegema R, Hagebeuk E, Gunning B, Deckers C, Berghuis B, Wegner I, Niks E, Jansen FE, Braun K, de Jong D, Rubboli G, Talvik I, Sander V, Uldall P, Jacquemont M-L, Nava C, Leguern E, Julia S, Gambardella A, d'Orsi G, Crichiutti G, Faivre L, Darmency V, Benova B, Krsek P, Biraben A, Lebre A-S, Jennesson M, Sattar S, Marchal C, Nordli DR, Lindstrom K, Striano P, Lomax LB, Kiss C, Bartolomei F, Lepine AF, Schoonjans A-S, Stouffs K, Jansen A, Panagiotakaki E, Ricard-Mousnier B, Thevenon J, de Bellescize J, Catenoix H, Dorn T, Zenker M, Müller-Schlüter K, Brandt C, Krey I, Polster T, Wolff M, Balci M, Rostasy K, Achaz G, Zacher P, Becher T, Cloppenborg T, Yuskaitis CJ, Weckhuysen S, Poduri A, Lemke JR, Møller RS, Baulac S. The landscape of epilepsy-related GATOR1 variants. Genet Med 2019;21:398–408.
- 25 Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. Cadd: predicting the deleteriousness of variants throughout the human genome. *Nucleic Acids Res* 2019;47:D886–94.
- 26 Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003;31:3812–4.
- 27 Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248–9.
- 28 Shen D, Hernandez CC, Shen W, Hu N, Poduri A, Shiedley B, Rotenberg A, Datta AN, Leiz S, Patzer S, Boor R, Ramsey K, Goldberg E, Helbig I, Ortiz-Gonzalez XR, Lemke JR, Marsh ED, Macdonald RL. *De novo GABRG2* mutations associated with epileptic encephalopathies. *Brain* 2017;140:49–67.
- 29 Coppola A, Cellini E, Stamberger H, Saarentaus E, Cetica V, Lal D, Djémié T, Bartnik-Glaska M, Ceulemans B, Helen Cross J, Deconinck T, Masi SD, Dorn T, Guerrini R, Hoffman-Zacharska D, Kooy F, Lagae L, Lench N, Lemke JR, Lucenteforte E, Madia F, Mefford HC, Morrogh D, Nuernberg P, Palotie A, Schoonjans A-S, Striano P, Szczepanik E, Tostevin A, Vermeesch JR, Van Esch H, Van Paesschen W, Waters JJ, Weckhuysen S,

- Zara F, De Jonghe P, Sisodiya SM, Marini C, Lehesjioki Anna-Elina, Craiu D, Talvik T, Caglayan H, Serratosa J, Sterbova K, Møller RS, Hjalgrim H, Lerche H, Weber Y, Helbig I, Spiczak S, Barba C, Bogaerts A, Boni A, Galizia EC, Chiari S, Gacomo G, Ferrari A, Guarducci S, Giglio S, Holmgren P, Leu C, Melani F, Novara F, Pantaleo M, Peeters E, Pisano T, Rosati A, Sander J, Schoeler N, Stankiewicz P, Striano S, Suls A, Traverso M, Vandeweyer G, Dijck A, Zuffardi O, EuroEPINOMICS-RES Consortium, EpiCNV Consortium. Diagnostic implications of genetic copy number variation in epilepsy plus. *Epilepsia* 2019;60:689–706.
- 30 Mei D, Parrini E, Marini C, Guerrini R. The impact of next-generation sequencing on the diagnosis and treatment of epilepsy in paediatric patients. *Mol Diagn Ther* 2017:21:357–73.
- 31 Wolking S, May P, Mei D, Møller RS, Balestrini S, Helbig KL, Altuzarra CD, Chatron N, Kaiwar C, Stöhr K, Widdess-Walsh P, Mendelsohn BA, Numis A, Cilio MR, Van Paesschen W, Svendsen LL, Oates S, Hughes E, Goyal S, Brown K, Sifuentes Saenz M, Dorn T, Muhle H, Pagnamenta AT, Vavoulis DV, Knight SJL, Taylor JC, Canevini MP, Darra F, Gavrilova RH, Powis Z, Tang S, Marquetand J, Armstrong M, McHale D, Klee EW, Kluger GJ, Lowenstein DH, Weckhuysen S, Pal DK, Helbig I, Guerrini R, Thomas RH, Rees MI, Lesca G, Sisodiya SM, Weber YG, Lal D, Marini C, Lerche H, Schubert J. Clinical spectrum of STX1B-related epileptic disorders. Neurology 2019;92:10.1212/WNL.0000000000007089.
- 32 Komulainen-Ebrahim J, Schreiber JM, Kangas SM, Pylkäs K, Suo-Palosaari M, Rahikkala E, Liinamaa J, Immonen E-V, Hassinen I, Myllynen P, Rantala H, Hinttala R, Uusimaa J. Novel variants and phenotypes widen the phenotypic spectrum of GABRG2-related disorders. *Seizure* 2019;69:99–104.
- 33 Crino PB. The mTOR signalling cascade: paving new roads to cure neurological disease. Nat Rev Neurol 2016;12:379–92.
- 34 Griffith JL, Wong M. The mTOR pathway in treatment of epilepsy: a clinical update. Future Neurol 2018;13:49–58.
- 35 Baldassari S, Licchetta L, Tinuper P, Bisulli F, Pippucci T. Gator1 complex: the common genetic actor in focal epilepsies. *J Med Genet* 2016;53:503–10.
- 36 Møller RS, Weckhuysen S, Chipaux M, Marsan E, Taly V, Bebin EM, Hiatt SM, Prokop JW, Bowling KM, Mei D, Conti V, de la Grange P, Ferrand-Sorbets S, Dorfmüller G, Lambrecq V, Larsen LHG, Leguern E, Guerrini R, Rubboli G, Cooper GM, Baulac S. Germline and somatic mutations in the MTOR gene in focal cortical dysplasia and epilepsy. Neurol Genet 2016;2:e118.
- 37 Corbett MA, Bellows ST, Li M, Carroll R, Micallef S, Carvill GL, Myers CT, Howell KB, Maljevic S, Lerche H, Gazina EV, Mefford HC, Bahlo M, Berkovic SF, Petrou S, Scheffer IE, Gecz J. Dominant KCNA2 mutation causes episodic ataxia and pharmacoresponsive epilepsy. Neurology 2016;87:1975–84.
- 38 Lal D, Pernhorst K, Klein KM, Reif P, Tozzi R, Toliat MR, Winterer G, Neubauer B, Nürnberg P, Rosenow F, Becker F, Lerche H, Kunz WS, Kurki MI, Hoffmann P, Becker AJ, Perucca E, Zara F, Sander T, Weber YG. Extending the phenotypic spectrum of RBFOX1 deletions: Sporadic focal epilepsy. Epilepsia 2015;56:e129–33.
- 39 Vanoye CG, Gurnett CA, Holland KD, George AL, Kearney JA. Novel Scn3a variants associated with focal epilepsy in children. *Neurobiol Dis* 2014;62:313–22.
- 40 Epilepsy Genetics Initiative. The epilepsy genetics initiative: systematic reanalysis of diagnostic exomes increases yield. *Epilepsia* 2019;60:797–806.